Construction and characterization of a recombinant adenoviral vector expressing human interleukin-12

Cancer Gene Therapy

Volumn 6, Issue 4, 1999, Pages 373-379

  Qiao, Jian ^a   Chen, Shu Hsia ^a   Pham Nguyen, Khiem B ^a   Mandeli, John ^a   Woo, Savio L C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Antitumor immunity; Gene therapy; Human interleukin 12; Recombinant adenoviral vector

Indexed keywords

INTERLEUKIN 12; PRIMER DNA; RECOMBINANT PROTEIN;

ADENOVIRUS; ANIMAL; ARTICLE; CELL CULTURE; CELL LINE; GENE VECTOR; GENETIC RECOMBINATION; GENETIC TRANSDUCTION; GENETICS; HUMAN; MOUSE; NUCLEOTIDE SEQUENCE;

ADENOVIRIDAE; ANIMALS; BASE SEQUENCE; CELL LINE; DNA PRIMERS; GENETIC VECTORS; HUMANS; INTERLEUKIN-12; MICE; RECOMBINANT PROTEINS; RECOMBINATION, GENETIC; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0033162420     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700061     Document Type: Article

References (41)

1. Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med. 1989;170:827-845.
2. Stern AS, Podlaski FJ, Hulmes JD, et al. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci USA. 1990;87:6808-6812.
3. Gubler U, Chua AO, Schoenhaut DS, et al. Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc Natl Acad Sci USA. 1991;88:4143-4147.
4. Chehimi J, Starr SE, Frank I, et al. Natural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients. J Exp Med. 1992;175:789-796.
5. Chehimi J, Valiante NM, D'Andrea A, et al. Enhancing effect of natural killer cell stimulatory factor (NKSF/ interleukin-12) on cell-mediated cytotoxicity against tumor-derived and virus-infected cells. Eur J Immunol. 1993; 23:1826-1830.
6. Soiffer RJ, Robertson MJ, Murray C, Cochran K, Ritz J. Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. Blood. 1993;82:2790-2796.
7. Wolf SF, Sieburth D, Sypek J. Interleukin 12: a key modulator of immune function. Stem Cells. 1994;12:154-168.
8. Heufler C, Koch F, Stanzl U, et al. Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-γ production by T helper 1 cells. Eur J Immunol. 1996;26:659-668.
9. Tsung K, Meko JB, Peplinski GR, Tsung YL, Norton JA. IL-12 induces Th1-directed antitumor response. J Immunol. 1997;158:3359-3365.
10. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med. 1993;178:1223-1230.
11. Nishimura T, Watanabe K, Yahata T, et al. Application of interleukin 12 to antitumor cytokine and gene therapy. Cancer Chemother Pharmacol. 1996;38:27-34.
12. Cohen J. IL-12 deaths: explanation and a puzzle. Science. 1995;270:908.
13. Nastala CL, Edington HD, McKinney TG, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol. 1994;153: 1697-1706.
14. Wolf SF, Temple PA, Kobayashi M, et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 1991;146:3074-3081.
15. Schoenhaut DS, Chua AO, Wolitzky AG, et al. Cloning and expression of murine IL-12. J Immunol. 1992;148: 3433-3440.
16. Tahara H, Zeh HJR, Storkus WJ, et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 1994;54:182-189.
17. Zitvogel L, Tahara H, Robbins PD, et al. Cancer immunotherapy of established tumors with IL-12: effective delivery by genetically engineered fibroblasts. J Immunol. 1995;155:1393-1403.
18. Tahara H, Lotze MT, Robbins PD, Storkus WJ, Zitvogel L. IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. Hum Gene Ther. 1995;6:1607-1624.
19. Bramson J, Hitt M, Gallichan WS, Rosenthal KL, Gauldie J, Graham FL. Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: in vitro and in vivo production of biologically active interleukin-12. Hum Gene Ther. 1996;7:333-342.
20. Bramson JL, Hitt M, Addison CL, Muller WJ, Gauldie J, Graham FL. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and longlasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther. 1996;7: 1995-2002.
21. Caruso M, Pham-Nguyen K, Kwong YL, et al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci USA. 1996;93:11302-11306.
22. Chen L, Chen D, Block E, O'Donnell M, Kufe DW, Clinton SK. Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer. J Immunol. 1997;159:351-359.
23. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 1997;36:59-74.
24. Tahara H, Lotze MT. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Ther. 1995;2:96-106.
25. Fang B, Eisensmith RC, Li XHC, Shedlovsky A, Dove W, Woo SLC. Gene therapy for phenylketonuria: phenotypic correction in a genetically deficient mouse model by adenovirus-mediated hepatic gene transfer. Gene Ther. 1994;1:247-254.
26. Graham FL, Prevec L. Manipulation of adenovirus vector. In: Murray EJ, ed. Methods in Molecular Biology: Gene Transfer and Expression Protocols, Volume 7. Clifton, NJ: The Human Press; 1991:109-128.
27. Bett AJ, Haddara W, Prevec L, Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA. 1994;91:8802-8806.
28. Kay MA, Landen CN, Rothenberg SR, et al. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc Natl Acad Sci USA. 1994;91:2353-2357.
29. Nanni P, Rossi I, De Giovanni C, et al. Interleukin 12 gene therapy of MHC-negative murine melanoma metastases. Cancer Res. 1998;58:1225-1230.
30. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst. 1995;87:581-586.
31. Sarmiento UM, Riley JH, Knaack PA, et al. Biologic effects of recombinant human interlcukin-12 in squirrel monkeys (Sciureus saimiri). Lab Invest. 1994;71:862-873.
32. Leonard JP, Sherman ML, Fisher GL, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-γ production. Blood. 1997; 90:2541-2548.
33. Ryffel B. Interleukin-12: role of interferon-γ in IL-12 adverse effects. Clin Immunol Immunopathol. 1997;83:18-20.
34. Lotze MT, Zitvogel L, Campbell R, et al. Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials. Ann N Y Acad Sci. 1996;795:440-454.
35. Sun Y, Jurgovsky K, Moller P, et al. Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. Gene Ther. 1998;5:481-490.
36. Zitvogel L, Tahara H, Cai Q, et al. Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. Hum Gene Ther. 1994; 5:1493-1506.
37. Zhang J, Asselin-Paturel C, Bex F, et al. Cloning of human IL-12 p40 and p35 DNA into the Semliki Forest virus vector: expression of IL-12 in human tumor cells. Gene Ther. 1997;4:367-374.
38. Zitvogel L, Robbins PD, Storkus WJ, et al. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur J Immunol. 1996;26:1335-1341.
39. Lasek W, Feleszko W, Golab J, et al. Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor α in mice. Cancer Immunol Immunother. 1997;45:100-108.
40. Zhang T, Kawakami K, Qureshi MH, Okamura H, Kurimoto M, Saito A. Interleukin-12 (IL-12) and IL-18 synergistically induce the fungicidal activity of murine peritoneal exudate cells against Cryptococcus neoformans through production of γ interferon by natural killer cells. Infect Immun. 1997;65:3594-3599.
41. Putzer BM, Hitt M, Muller WJ, Emtage P, Gauldie J, Graham FL. Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Proc Natl Acad Sci USA. 1997;94:10889-10894.